J 2017

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

VERHOEF, G., T. ROBAK, H.Q. HUANG, H. PYLYPENKO, N. SIRITANARATKUL et. al.

Základní údaje

Originální název

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Autoři

VERHOEF, G. (56 Belgie), T. ROBAK (616 Polsko), H.Q. HUANG (156 Čína), H. PYLYPENKO (804 Ukrajina), N. SIRITANARATKUL (764 Thajsko), J. PEREIRA (76 Brazílie), J. DRACH (40 Rakousko), Jiří MAYER (203 Česká republika, garant, domácí), R. OKAMOTO (392 Japonsko), L.X. PEI (840 Spojené státy), B. ROONEY (826 Velká Británie a Severní Irsko), A. CAKANA (826 Velká Británie a Severní Irsko), H. van de VELDE (840 Spojené státy) a F. CAVALLI (756 Švýcarsko)

Vydání

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2017, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 9.090

Kód RIV

RIV/00216224:14110/17:00098741

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000402490900026

Klíčová slova anglicky

3 LYM-3002

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 20. 3. 2018 18:52, Soňa Böhmová

Anotace

V originále

In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P<0.001). This post-hoc analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP versus R-CHOP in LYM-3002. Patients were randomized to six to eight 21-day cycles of VR-CAP or R-CHOP. Outcomes included progression-free survival, duration of response (both assessed by an independent review committee), and time to next anti-lymphoma treatment, evaluated by response (complete response/unconfirmed complete response and partial response), MIPI risk status, and maximum reduction of lymph-node measurements expressed as the sum of the product of the diameters. Within each response category, the median progression-free survival was longer for patients given VR-CAP than for those given R-CHOP (complete response/unconfirmed complete response: 40.9 versus 19.8 months; partial response: 17.1 versus 11.7 months, respectively); similarly, the median time to next anti-lymphoma treatment was longer among the patients given VR-CAP than among those treated with R-CHOP (complete response/unconfirmed complete response: not evaluable versus 26.6 months; partial response: 35.3 versus 24.3 months). Within the complete/unconfirmed complete and partial response categories, improvements in progression-free survival, duration of response and time to next anti-lymphoma treatment were more pronounced in patients with low- and intermediate-risk MIPI treated with VR-CAP than with R-CHOP. In each response category, more VR-CAP than R-CHOP patients had a sum of the product of the diameters nadir of 0 during serial radiological assessments. Results of this post-hoc analysis suggest a greater duration and quality of response in patients treated with VR-CAP in comparison with those treated with R-CHOP, with the improvements being more evident in patients with low-and intermediate-risk MIPI. LYM-3002 ClinicalTrials.gov: NCT00722137.